Scope and Claims Analysis for US Patent 11,951,096 (Nirogacestat, Desmoid Tumor Dose-Management Methods)
US 11,951,096 is a method-of-treatment patent that claims nirogacestat dosing and interruption rules for patients with desmoid tumor who receive 150 mg twice daily (free base equivalent), followed by specific dose interruption, dose reduction to 100 mg twice daily, or permanent discontinuation triggered by predefined adverse events and exposure metrics. The core claim is claim 1, with multiple dependent claims that narrow patient genotypes, disease context, and exposure ranges (Cmax and AUCtau), and broaden the commercial cover via multiple method variants for refractory, treatment-naive, and familial adenomatous polyposis (FAP)-related populations.
What does the patent actually cover?
Drug: nirogacestat (and pharmaceutically acceptable salts), including nirogacestat dihydrobromide (claim 17).
Indication: desmoid tumor (claims 1, 13-15, 24-25).
Regimen anchor: 150 mg (free base equivalent) orally twice daily as the starting dose (claims 1, 13, 15).
Action framework: defined clinical stopping and restarting logic for Grade 3-4 diarrhea, Grade 3-4 electrolyte disturbances (hypophosphatemia, hypokalemia), and hepatotoxicity (ALT/AST thresholds), plus an additional rule for other severe/life-threatening or persistent intolerable Grade 2 adverse events (claim 2).
Exposure gate (claim 1): at steady state on 150 mg BID, an exposure window of AUCtau ~ 2200 to 4800 ng·h/mL is recited as part of claim 1 (and not in the other claim subsets unless explicitly included elsewhere).
What are the enforceable claim boundaries in claim 1?
Claim 1 is the broadest independent claim you provided. It is a single integrated method claim with multiple alternative trigger branches (a)-(e) plus a steady-state exposure limitation (AUCtau). It is not merely “nirogacestat reduces desmoid tumor toxicity.” It is dosing-management during therapy, where the method includes specific clinical decision points.
Claim 1 structure (mechanistic legal scope)
- Patient and indication: “therapeutic treatment of desmoid tumor” in a patient in need thereof.
- Dose administered initially: 150 mg (free base equivalent dose) nirogacestat (or salt) twice daily.
- Then includes one or more of five specific actions:
- (a) Diarrhea management
- Trigger: Grade 3 or 4 diarrhea persisting at least 3 days despite medical therapy
- Action: withhold until diarrhea resolves to Grade ≤1 or baseline
- Restart dose: 100 mg BID
- (b) Hypophosphatemia management
- Trigger: Grade 3 or 4 hypophosphatemia persisting at least 3 days despite replacement therapy
- Action: withhold until resolved to Grade ≤1 or baseline
- Restart dose: 100 mg BID
- (c) Hypokalemia management
- Trigger: Grade 3 or 4 hypokalemia despite replacement therapy
- Action: withhold until resolved to Grade ≤1 or baseline
- Restart dose: 100 mg BID
- (d) Hepatic enzyme elevation (moderate)
- Trigger: ALT or AST = 3 to 5 × ULN
- Action: withhold until ALT/AST resolved to ≤3 × ULN or baseline
- Restart dose: 100 mg BID
- (e) Hepatic enzyme elevation (severe)
- Trigger: ALT or AST > 5 × ULN
- Action: permanent discontinuation
- Exposure requirement (steady state on 150 mg BID):
- AUCtau of nirogacestat from about 2200 to about 4800 ng·h/mL
Practical implication for infringement design
A would-be infringer must avoid performing the method steps as recited (including the trigger durations/grade thresholds) and the exposure condition in claim 1. If a clinician manages AEs by different thresholds, different hold durations, different restart doses, or different discontinuation triggers, the specific method recited in claim 1 may not be met.
How do dependent claims narrow or expand risk for generics and follow-on products?
Dependent claims operate in two main ways:
- Narrowing patient populations (genotype, treatment-naive vs refractory, gender, FAP family history, intraabdominal tumors)
- Narrowing pharmacokinetic ranges and alternative method compositions (Cmax windows, AUCtau window in a dependent claim, and “method comprises” list variants)
Claim 2: “Other severe/life-threatening or persistent intolerable Grade 2” pathway
- Adds an extra decision branch beyond (a)-(e):
- For another severe adverse reaction or life-threatening adverse reaction or persistent, intolerable Grade 2 adverse event
- Withhold until adverse reaction resolves to Grade ≤1 or baseline
- Restart logic: after benefit/recurrence assessment, restart at 100 mg BID
- If severe or life-threatening AE recurs at 100 mg BID: permanent discontinuation
Scope effect: adds real-world flexibility to cover additional AE management practices, but still anchors dosing to 100 mg BID and permanent discontinuation upon recurrence.
Claims 3-8: alternative dependent claim “single-branch” or “complete list” formulations
- Claims 3-6 focus on individual triggers among (b)-(e).
- Claim 7 and claim 8 reproduce “method comprises” structures that list (a)-(e) and optionally include (f) from claim 2.
Scope effect: strengthens enforceability by providing multiple claim pathways that may be asserted even if one branch is disputed as not performed. It increases the number of likely matching practices.
Claim 9: dermatologic reaction branch
- If Grade 3 dermatologic reaction: withhold until resolved to ≤Grade 1, then restart at 100 mg BID
Scope effect: expands the trigger list beyond the main five (diarrhea, hypophosphatemia, hypokalemia, ALT/AST moderate, ALT/AST severe) into dermatology.
Claims 10-12: genotype/disease subtype limitations
- Claim 10: APC tumor suppressor gene mutation
- Claim 11: CTNNB1 (β-catenin) mutation
- Claim 12: intraabdominal tumors
Scope effect: narrows coverage to genetically or anatomically defined subsets. This can matter in licensing or defense because genotype confirmation is a fact issue, but it can also narrow design-around because a sponsor targeting a specific patient subgroup may still land inside these dependent claims.
Claims 13-15: three independent-method variants tied to FAP family history, refractory/recurrent, and treatment-naive
These claims look like independent claims in practice, each reciting:
- 150 mg BID starting dose
- same (a)-(e) dose-management logic
- plus a population modifier:
- Claim 13: “family history of familial adenomatous polyposis”
- Claim 14: “refractory or recurrent disease after previous treatment”
- Claim 15: “treatment naive patient”
Scope effect: these variants increase enforcement likelihood across real-world clinical categories and reduce reliance on whether a specific genotype model is available.
Claim 16: post-menopausal woman
- Adds demographic narrowing.
Scope effect: mostly relevant as a narrower “fallback” claim depending on trial and prescribing data.
Claim 18-22: Cmax ranges tied to initial 150 mg BID or steady-state exposure
- Claim 18: Cmax 480 to 950 ng/mL
- Claim 19: Cmax 550 to 1100 ng/mL
- Claim 20: Cmax 600 to 800 ng/mL (depends from claim 19)
- Claim 21: Cmax at steady state 300 to 700 ng/mL
- Claim 22: Cmax at steady state 400 to 600 ng/mL (depends from claim 21)
Scope effect: these claims can be asserted only if pharmacokinetic data for the dosing event in the treated patient matches those windows. They also create a “PK-anchored” infringement argument when multiple AE management variations exist.
Claim 23: AUCtau window at steady state
- AUCtau steady state on 150 mg BID = 3000 to 3700 ng·h/mL
Scope effect: this is an additional PK-dependent narrowing. Importantly, claim 1 already includes AUCtau 2200 to 4800 ng·h/mL, so claim 23 provides a narrower band that could be asserted in parallel if data supports it.
Claims 24-25: “method comprises” list versions of the full AE-management set
- Claim 24: reproduces (a)-(e) list for claim 1
- Claim 25: reproduces (a)-(e) list for claim 15
Scope effect: provides more enforceability hooks tied to the dependent “treatment-naive” population variant.
Where are the key “design-around” levers?
For R&D and freedom-to-operate planning, the enforceable levers are the explicit thresholds and restart/discontinuation decisions:
Threshold and duration levers
- Diarrhea: Grade 3-4 and persisting at least 3 days despite medical therapy
- Hypophosphatemia: Grade 3-4, persisting at least 3 days despite replacement therapy
- Hypokalemia: Grade 3-4 “despite replacement therapy” (no “at least 3 days” text in your provided claim language, which matters)
- Hepatic enzymes:
- 3 to 5 × ULN: hold and restart at 100 mg BID
- >5 × ULN: permanent discontinuation
Dose lever
- Restart dose after holds: 100 mg BID
- Starting dose: 150 mg BID
- Permanent discontinuation is triggered only by ALT/AST >5× ULN in (e), and by recurrence of severe/life-threatening AE at 100 mg BID in (f)
Exposure lever (claim 1)
- AUCtau between ~2200 and ~4800 ng·h/mL at steady state on 150 mg BID
What is the patent landscape position of US 11,951,096 relative to nirogacestat coverage?
Based only on the claim language you supplied, US 11,951,096 is a method-of-treatment/dose-management patent, not a composition-of-matter claim. Its landscape role is to:
- lock in specific AE management steps for desmoid tumor while on nirogacestat,
- tie the dosing management to fixed dosing amounts (150 mg BID and 100 mg BID),
- and add PK exposure criteria (AUCtau; and in dependents, Cmax ranges and a narrower AUCtau band).
Landscape segmentation by claim mechanics
| Patent type (by claim mechanics) |
What it does |
Likely buyer/defender priority |
Where this patent fits |
| Composition-of-matter |
Blocks generic active ingredient entry |
Highest for exclusivity |
Not shown in your claims |
| Use/indication |
Blocks “treat desmoid tumor with nirogacestat” |
High for market exclusivity |
Yes (desmoid tumor treatment) |
| Dose and AE management method |
Blocks specific clinical holds, dose reductions, discontinuations, and sometimes PK windows |
Medium to high in litigation leverage |
Yes, dominant feature here |
What does the claim set imply about trial evidence and clinical operations?
Even without the specification text, the claim drafting implies reliance on measured exposures and graded AEs:
- Claim 1 includes steady-state AUCtau window.
- Dependent claims include multiple Cmax ranges and a narrow AUCtau band.
- AE thresholds use CTCAE-style Grade 3-4 language and ALT/AST × ULN thresholds.
- Restart and discontinuation actions match a typical label-style dose-interruption algorithm structure: hold, resolve to Grade ≤1/baseline, restart at reduced dose, or permanently stop at severe liver injury.
This structure increases the odds that the method is grounded in actual dosing protocols from clinical development.
Claim-by-claim “coverage map” for desmoid tumor scenarios
Patient eligibility modifiers
- General desmoid tumor patients needing therapy: claim 1
- Family history of FAP: claim 13
- Refractory/recurrent after prior therapy: claim 14
- Treatment naive: claim 15
- Intraabdominal tumors: claim 12
- APC mutation: claim 10
- CTNNB1 mutation: claim 11
- Post-menopausal woman: claim 16
AE-trigger coverage (hold/restart/discontinue)
| Trigger |
Condition in claim language |
Action |
Restart/discontinue |
| Diarrhea |
Grade 3-4, persisting ≥3 days, despite medical therapy |
Hold until Grade ≤1/baseline |
Restart 100 mg BID |
| Hypophosphatemia |
Grade 3-4, persisting ≥3 days, despite replacement |
Hold until Grade ≤1/baseline |
Restart 100 mg BID |
| Hypokalemia |
Grade 3-4, despite replacement |
Hold until Grade ≤1/baseline |
Restart 100 mg BID |
| ALT/AST moderate |
3 to 5 × ULN |
Hold until resolved to ≤3 × ULN/baseline |
Restart 100 mg BID |
| ALT/AST severe |
>5 × ULN |
Permanent stop trigger |
Permanently discontinue |
| Dermatologic reaction |
Grade 3 dermatologic reaction |
Hold until Grade ≤1 |
Restart 100 mg BID |
| Other severe/life-threatening or persistent intolerable Grade 2 |
As defined in claim 2 (f) |
Hold until Grade ≤1/baseline, then restart after benefit/recurrence assessment |
Restart 100 mg BID; if recurs at 100 mg BID, permanently discontinue |
Where does exposure language tighten infringement?
Claim 1: AUCtau gate on 150 mg BID
- AUCtau from about 2200 to about 4800 ng·h/mL at steady-state exposure after administering 150 mg BID.
Dependent exposure claims
- Cmax windows:
- 480-950 ng/mL (claim 18)
- 550-1100 ng/mL (claim 19)
- 600-800 ng/mL (claim 20)
- Steady-state Cmax 300-700 ng/mL (claim 21)
- Steady-state Cmax 400-600 ng/mL (claim 22)
- AUCtau narrow band:
- 3000-3700 ng·h/mL (claim 23)
Landscape effect: these PK constraints provide claim differentiation across specific PK outcomes, which can matter in enforcement because measurement availability (PK sampling and assay) varies across clinical practice.
Key Takeaways
- US 11,951,096 claims nirogacestat dosing-management for desmoid tumor: start 150 mg BID, then use hold/restart at 100 mg BID for defined AE thresholds and permanent discontinuation for ALT/AST >5× ULN.
- Claim 1 adds a steady-state exposure limitation: AUCtau ~2200 to ~4800 ng·h/mL after 150 mg BID.
- Dependent claims broaden enforceability through additional AE categories (notably dermatologic Grade 3), patient subgroups (treatment naive, refractory, FAP family history, genotype, intraabdominal tumors), and PK ranges (Cmax and narrower AUCtau).
- The principal design-around levers are the specific Grade/time thresholds, the dose level for restart (100 mg BID), the ALT/AST discontinuation trigger (>5× ULN), and the claim-embedded exposure window in claim 1.
FAQs
1) Is US 11,951,096 a composition-of-matter patent?
No. Based on the claims provided, it is a method-of-treatment patent covering dosing and interruption decisions during nirogacestat therapy.
2) What is the starting dose and the restart dose in the core claim?
Starting dose: 150 mg (free base equivalent) orally twice daily.
Restart dose after holds: 100 mg (free base equivalent) twice daily (for the specified AE triggers).
3) When does the patent require permanent discontinuation?
In claim 1’s (e): ALT or AST >5× ULN triggers permanent discontinuation. Claim 2 also supports permanent discontinuation upon recurrence of specified severe/life-threatening or persistent intolerable Grade 2 adverse events at the 100 mg BID restart dose.
4) What exposure metric is tied to claim 1?
Claim 1 ties infringement to a steady-state AUCtau window of about 2200 to 4800 ng·h/mL after dosing 150 mg BID.
5) Do dependent claims include PK windows beyond AUCtau?
Yes. Dependent claims include Cmax ranges (including multiple windows for initial and steady-state exposure) and a narrower AUCtau range of 3000 to 3700 ng·h/mL.
References
[1] US Patent 11,951,096 (claims as provided by user).
